On Level Of Treg Cells In Peripheral Blood Of Patients With Chronic Hepatitis B And HBsAg Early Change Of Predictive Value Of Adefovir Dipivoxil

ObjectiveChronic hepatitis B (CHB) patients receiving adefovir dipivoxil (ADV) antiviral therapy inperipheral blood of CD4 + CD25 + T-lymphocytes (suppressor T lymphocytes, referred to as thelevel of Treg cells) and the course of treatment, early changes and long-term clinical efficacy ofthe serum HBsAg levels, provide the basis for the optimization of the clinical antiviral treatment.Materials and Methods1. Clinical data: September 2010 September to 2011, the First Hospital of Shanxi MedicalUniversity, infection disease outpatient and inpatient diagnosis consistent with chronic hepatitisB prevention and treatment guidelines and has anti-viral indications, the nucleoside analoguesuntreated slow hepatitis B patients, treatment follow-up of 48 weeks, with complete data, 92cases; choose the examination center of the First Hospital of Shanxi Medical University, for thesame period 10 cases of healthy persons as normal controls.2. Methods: CHB patients before treatment, all specimens from early morning fasting blood4ml spare, to give oral ADV10mg / d anti-viral treatment. Before treatment, treatment of 4 weeks,12 weeks, 24 weeks and 48 weeks of blood collection unified detection of HBsAg and HBeAg inHBVDNA in quantitative and alanine aminotransferase (ALT). Serum HBVDNA in the 48weeks of treatment, HBeAg serum school conversion and ALT levels of 92 CHB patients withcomplete data is divided into complete response, partial response and no response to three groups.By flow cytometry to detect the expression level of 92 CHB patients with ADV before treatmentand Treg cells in peripheral blood of 10 healthy controls. ADV antiviral therapy early serumHBsAg levels changes the analysis of CD4 + CD25 + T lymphocyte levels in CHB patients withCHB patients with ADV antiviral therapy the clinical efficacy of 48 weeks.Results1. In 92 cases of CHB patients, treated for 48 weeks with complete response group in 11cases, HBsAg levels since the initial treatment to 24 weeks was decreased; partial responsegroup in 69 cases, HBsAg levels since the initial treatment to 12 weeks continued to decline, but12to 24 weeks to appear rebound; nonresponse group 12 cases, since the initial treatment to 24weeks HBsAg level fluctuation.2. In 92 patients with CHB before antiviral therapy on peripheral blood Treg cells were significantly higher than in the normal control group, P < 0.001. Which, after 48 weeks oftreatment nonresponse group was obviously higher than that of complete response and partialresponse group, partial response group was higher than that in complete response group, P <0.001; complete response group (3.65 +0.85) %, although higher than those in the control group(3.03 +0.66) %, but no significant difference, P = 0.259.ConclusionPatients with CHB ADV before antiviral therapy on peripheral blood Treg cell level andantiviral therapy within 24 weeks of serum HBsAg level decreased the ADV antiviral efficacymay have predictive value.